Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial

Hossein Faramarzi, Amirhossein Sahebkar, View ORCID ProfileAhmad Hosseinpour, Vahid Khaloo, Parisa Chamanpara, Mohammad Reza Heydari, Sajad Najafi, Fatemeh Fotoohi Khankahdany, Ahmad Movahedpour
doi: https://doi.org/10.1101/2021.11.20.21266229
Hossein Faramarzi
1Department of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail address:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hossainfaramarzi@yahoo.com
Amirhossein Sahebkar
2Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran E-mail address:
3Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sahebkara@mums.ac.ir
Ahmad Hosseinpour
4Shimi Teb Salamat Co., Shiraz, Iran. E-mail address:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ahmad Hosseinpour
  • For correspondence: ahosseinpour3@gmail.com fotoohifati@yahoo.com
Vahid Khaloo
5Ali Asghar Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail address:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: khaloov@yahoo.com
Parisa Chamanpara
6Department of Biostatistics, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail address:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: p.chamanpara@yahoo.com
Mohammad Reza Heydari
7Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail address:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: heydari280@yahoo.com
Sajad Najafi
8Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail address:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sajadnajafi1990@yahoo.com
Fatemeh Fotoohi Khankahdany
4Shimi Teb Salamat Co., Shiraz, Iran. E-mail address:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fotoohifati@yahoo.com
Ahmad Movahedpour
9Behbahan Faculty of Medical Sciences, Behbahan, Iran. E-mail address:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ahmad.movahed14@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Despite an increasing number of studies, there is as yet no efficient antiviral treatment developed for the disease. In this clinical trial, we examined the efficacy of a novel herbal antiviral preparation comprising Zataria multiflora Boiss, Glycyrrhiza glabra, Cinnamomum Vermont, Allium sativuml, and Syzygium aromaticum in critically ill patients with COVID-19 patients.

Methods A total number of 120 ICU-admitted patients requiring pulmonary support with a diagnosis of COVID-19 pneumonia were recruited to the trial. Participants were equally randomized to receive either the novel antiviral preparation sublingually, for up to two consecutive weeks or till discharge, or normal saline as the matching placebo. Clinical and laboratory parameters as well as survival rates were compared between the two groups at the study end.

Results The cumulative incidence of death throughout the study period was 8.33% in the medication group and 60% in the placebo group (risk ratio: 0.14; 95% confidence interval [CI], 0.05 to 0.32; P<0.001). Survival rates were significantly higher in the treatment group. Additionally, on day 7, several laboratory factors including white blood cells (WBCs) count, C-reactive protein (CRP), and SpO2 were improved in patients treated with the novel antiviral preparation compared with the placebo group.

Conclusion The novel antiviral preparation tested in this trial significantly improved the survival rate and reduced mortality in critically ill patients with COVID-19. Thus, this preparation might be suggested as a potentially promising COVID-19 treatment.

Funded by Shimi Teb Salamat Co., Shiraz, Iran, and registered on the Iranian registry of clinical trials (registration No. IRCT20200509047373N2).

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

IRCT20200509047373N2

Funding Statement

This study was supported in full by Shimi Teb Salamat Co., Shiraz, Iran.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The research was approved by the Ethics Committee of the Shiraz University of Medical Sciences (registration No. IR.SUMS.REC.1399.1367).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

http://www.irct.ir

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 25, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
Hossein Faramarzi, Amirhossein Sahebkar, Ahmad Hosseinpour, Vahid Khaloo, Parisa Chamanpara, Mohammad Reza Heydari, Sajad Najafi, Fatemeh Fotoohi Khankahdany, Ahmad Movahedpour
medRxiv 2021.11.20.21266229; doi: https://doi.org/10.1101/2021.11.20.21266229
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
Hossein Faramarzi, Amirhossein Sahebkar, Ahmad Hosseinpour, Vahid Khaloo, Parisa Chamanpara, Mohammad Reza Heydari, Sajad Najafi, Fatemeh Fotoohi Khankahdany, Ahmad Movahedpour
medRxiv 2021.11.20.21266229; doi: https://doi.org/10.1101/2021.11.20.21266229

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Intensive Care and Critical Care Medicine
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1099)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9781)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2317)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (605)
  • Hematology (238)
  • HIV/AIDS (506)
  • Infectious Diseases (except HIV/AIDS) (11655)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (239)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2146)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (365)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (312)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2187)
  • Public and Global Health (4672)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)